Fesoterodine Fumarate

富马酸非索罗定

Report date: 2024/06/11 20:00:08
NME

Base Information

Drug NameFesoterodine Fumarate
Drug Alias Namefesoterodina弗斯特罗定富马酸盐fesoterodinum富马酸菲索特啶非特罗定 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptor
Therapy Area/IndicationsUrinary Incontinence, UrgeUrinary Incontinence, StressUrinary Incontinence +[7] 
Global Approved IndicationsUrinary IncontinenceUrinary Bladder, Overactive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2007/04/20
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaClinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Europe Ma EeigHui Zhi Pharmaceutical (Dalian) Co Ltd
Inactive CompaniesThe University Of British ColumbiaUniversity Of North Carolina At Chapel HillUniversity Of Pennsylvania
Active IndicationsUrinary IncontinenceUrinary Bladder, OveractiveUrinary Bladder, Neurogenic
Inactive IndicationsUrinary Incontinence, UrgeUrinary Incontinence, StressUrologic Diseases +[4] 

Other Information

ATC CodeG04BD11
Related LinksWikipediaDrugBankKEGG